IP Library Granted Patent US 10,441,630
Granted Patent B2
US 10,441,630 · App. 15/153,640 · Granted Oct 15, 2019

Topical formulations and uses thereof

Inventors: Ashim K. Mitra (Overland Park, KS); Sidney L. Weiss (Randolph, NJ); Eugene J. McNally (Fitchburg, WI)
Assignee: SUN PHARMA GLOBAL FZE
A61K38/13A61K9/0048A61K9/1075A61K31/202A61K47/10A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,441,630
App. No.
15/153,640
Granted
Oct 15, 2019
Kind
B2
Abstract

Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.

Claims (10)

1. An aqueous clear nanomicellar ophthalmic formulation, comprising:

an active agent,

0.5-4.5% by weight of a polymer comprising HCO-40, HCO-60, HCO-80, HCO-100, polyoxyl 35 castor oil or combinations thereof; and

0.02-0.08% of a polyalkoxylated alcohol.

2. The aqueous clear nanomicellar ophthalmic formulation of claim 1 , wherein said polymer comprises HCO-40, HCO-60, HCO-80, HCO-100 or combinations thereof.

3. The aqueous clear nanomicellar ophthalmic formulation of claim 1 , wherein said polyalkoxylated alcohol is Octoxynol-40.

4. The aqueous clear nanomicellar ophthalmic formulation of claim 2 , wherein said polymer is HCO-40.

5. The aqueous clear nanomicellar ophthalmic formulation of claim 2 , wherein said polymer is HCO-60.

6. The aqueous clear nanomicellar ophthalmic formulation of claim 1 , wherein said polymer is 1-4% by weight.

7. The aqueous clear nanomicellar ophthalmic formulation of claim 3 , wherein Octoxynol-40 is 0.05% by weight.

Assignments (3)
MERGER Recorded Mar 28, 2022
From: SUN PHARMA GLOBAL FZE
To: SUN PHARMACEUTICAL INDUSTRIES LIMITED
Reel/Frame 059513/0463 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: OCULAR TECHNOLOGIES SARL
To: SUN PHARMA GLOBAL FZE
Reel/Frame 044380/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2016
From: MITRA, ASHIM K.; WEISS, SIDNEY L.; MCNALLY, EUGENE J.
To: OCULAR TECHNOLOGIES SARL
Reel/Frame 038579/0837 →
Continuity (4)
Continuation 14629883 · Feb 24, 2015
Continuation PCTUS2013056513 · Aug 23, 2013
Provisional Application 61693189 · Aug 24, 2012
Related Publication 20160256521A1 · Sep 8, 2016
Cited By (2)
US 12,564,572 US 12,564,573